People: Globus Medical Inc (GMED.N)
GMED.N on New York Stock Exchange
16.75USD
1 Aug 2013
16.75USD
1 Aug 2013
Price Change (% chg)
$-0.01 (-0.06%)
$-0.01 (-0.06%)
Prev Close
$16.76
$16.76
Open
$16.82
$16.82
Day's High
$16.88
$16.88
Day's Low
$16.55
$16.55
Volume
78,570
78,570
Avg. Vol
137,319
137,319
52-wk High
$19.90
$19.90
52-wk Low
$10.26
$10.26
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
David Paul |
46 | Chairman of the Board, Chief Executive Officer | |
David Demski |
55 | 2008 | President, Chief Operating Officer, Director |
Richard Baron |
51 | 2012 | Chief Financial Officer, Senior Vice President |
A. Brett Murphy |
48 | 2011 | Executive Vice President, US Sales |
David Davidar |
47 | 2003 | Vice President - Operations, Director |
Daniel Lemaitre |
59 | 2011 | Independent Director |
Robert Liptak |
49 | 2007 | Independent Director |
Ann Rhoads |
47 | 2011 | Independent Director |
Kurt Wheeler |
60 | 2007 | Independent Director |
Biographies
| Name | Description |
|---|---|
David Paul |
Mr. David C. Paul is Chairman of the Board, Chief Executive Officer of Globus Medical, Inc. Prior to founding Globus, Mr. Paul was employed at Synthes from March 1996 to January 2003 in various positions. He served as Director of Product Development for Synthes in his last position, where he was responsible for product development and marketing functions. Prior to Synthes, Mr. Paul worked as a Research Engineer in biomaterials research at Temple University from 1994 to 1995. Mr. Paul is a named inventor on approximately 45 patents and 74 pending patent applications. Mr. Paul received a B.S. in Mechanical Engineering from the University of Madras, and an M.S. in Computer Integrated Mechanical Engineering Systems from Temple University. Mr. Paul also currently serves as a member of the board of directors of Operating Room Safety LLC, a privately-held company. |
David Demski |
Mr. David M. Demski is President, Chief Operating Officer, Director of Globus Medical, Inc. Mr. Lemaitre is the Chief Executive Officer of White Pine Medical, a venture-backed medical device start-up company, and has served in that capacity since June 2009. Prior to White Pine Medical, Mr. Lemaitre served as the President and Chief Executive Officer of CoreValve, a privately-held company focused on percutaneous aortic valve replacement, from April 2008 until its acquisition by Medtronic, Inc., a publicly-traded medical device company, in April 2009. From 2005 until March 2008, Mr. Lemaitre was a Senior Vice President at Medtronic, where he led the company's strategic planning and corporate development. Prior to joining Medtronic, Mr. Lemaitre spent 28 years as an investment analyst in the medical device field. This included 18 years with SG Cowen, where he was a managing director and led the healthcare research team, and six years with Merrill Lynch. Mr. Lemaitre holds a B.A. in Economics from Bethany College and an M.B.A. from Bowling Green State University. Mr. Lemaitre also currently serves on the board of directors of Endologix, Inc. (NASDAQ:ELGX) and as the Chairman of Bioventus LLC, a privately-held medical device company. |
Richard Baron |
Mr. Richard A. Baron CPA, is Chief Financial Officer, Senior Vice President of Globus Medical, Inc. Prior to joining Globus, Mr. Baron served as an independent consultant to various early stage biotech and technology companies from April 2011 to January 2012. From May 2008 through April 2011, Mr. Baron served as Vice President, Finance and Chief Financial Officer of Avid Radiopharmaceuticals, a biotech company developing an imaging agent for Alzheimer's, which was sold to Eli Lilly in November 2011. From March 2007 to June 2008, Mr. Baron served as Senior Vice President, Finance and Chief Financial Officer of eResearch Technology, Inc. (NASDAQ: ERES). Mr. Baron also served as Vice President, Finance and Chief Financial Officer of Animas Corporation, a manufacturer and distributor of insulin infusion pumps (NASDAQ: PUMP), from May 2000 through its sale to Johnson & Johnson in February 2007. Prior to that time, Mr. Baron served as Vice President, Finance and Chief Financial Officer for Genex Services, a managed care provider for workers compensation and disability, and Marsam Pharmaceuticals Inc., a generic manufacturer of injectable anti-infectives, and was a manager with the Financial Advisory Services and Emerging Business Services groups at PricewaterhouseCoopers. Mr. Baron holds a B.S. in Economics, concentration in Accounting, from the Wharton School of the University of Pennsylvania. |
A. Brett Murphy |
Mr. A. Brett Murphy is Executive Vice President, US Sales of Globus Medical, Inc. Mr. Murphy served as Vice President, U.S. Sales-West, from November 2006 to February 2011, and as the Area Director for South region from June 2005 to November 2006. Prior to joining Globus, Mr. Murphy served in various sales and management roles at Synthes from July 1995 to May 2005. Between November 1992 and June 1995, Mr. Murphy was a sales representative for Smith & Nephew Richards. Mr. Murphy also served as an officer in the United States Marine Corps between 1987 and 1992. Mr. Murphy received a B.S. in General Studies from Louisiana State University. |
David Davidar |
Mr. David D. Davidar is Vice President - Operations, Director of Globus Medical, Inc. Prior to joining Globus, Mr. Davidar served as the Executive Director of Highway Home, an assisted living facility, from 1995 to 2003. Mr. Davidar also served in a management capacity for Pizza Hut, Inc. from 1993 to 1995. Mr. Davidar received a B.Com. in Commerce, Economics and Management from the University of Madras, a Post-Graduate diploma in Personnel Management at the Madras School of Social Work, and an M.B.A. from Bloomsburg University. |
Daniel Lemaitre |
Mr. Daniel T. Lemaitre is Independent Director of Globus Medical, Inc. Currently, Mr. Lemaitre is the Chief Executive Officer of White Pine Medical, a venture-backed medical device start-up company, and has served in that capacity since June 2009. Prior to White Pine Medical, Mr. Lemaitre served as the President and Chief Executive Officer of CoreValve, a privately-held company focused on percutaneous aortic valve replacement, from April 2008 until its acquisition by Medtronic, Inc., a publicly-traded medical device company, in April 2009. From 2005 until March 2008, Mr. Lemaitre was a Senior Vice President at Medtronic, where he led the company's strategic planning and corporate development. Prior to joining Medtronic, Mr. Lemaitre spent 28 years as an investment analyst in the medical device field. This included 18 years with SG Cowen, where he was a managing director and led the healthcare research team, and six years with Merrill Lynch. Mr. Lemaitre holds a B.A. in Economics from Bethany College and an M.B.A. from Bowling Green State University. Mr. Lemaitre also currently serves on the board of directors of Endologix, Inc. (NASDAQ:ELGX) and as the Chairman of Bioventus LLC, a privately-held medical device company. |
Robert Liptak |
Mr. Robert W. Liptak is Independent Director of Globus Medical, Inc. He has been Managing Director of Clarus Ventures, LLC, a life sciences venture capital firm, since its inception in 2005. He has served as one of directors since July 2007 and is a member of Compensation Committee and Audit Committee. He has over 20 years of experience in investment management focusing primarily on the establishment and management of various investment management businesses, including as a General Partner in MPM Capital, L.P., a healthcare venture capital firm, from 2001 to 2008. From 1995 to 2001, Mr. Liptak was a Partner with the Geometry Group, a diversified asset management firm focused on establishing investment management firms. From 1992 to 1995, Mr. Liptak was Vice President of Finance for Global Asset Management (USA) Inc., an asset management firm, and he began his career in 1986 with Price Waterhouse where he was a Manager in its Capital Markets Group. Mr. Liptak holds a B.A. in Accounting and Finance from LaSalle University and an M.B.A. from Columbia University, and is a certified public accountant. |
Ann Rhoads |
Ms. Ann D. Rhoads is Independent Director of Globus Medical, Inc. Ms. Rhoads is the Executive Vice President and Chief Financial Officer of Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company, and has served in that capacity since March 2010. From 2000 through the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. From 1998 to 2000, she was Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was a Vice President of The Sprout Group, an institutional venture capital firm. Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and a M.B.A. from the Harvard Graduate School of Business Administration. Ms. Rhoads also previously served on the board of directors of Novellus Systems, Inc. (NASDAQ:NVLS) from 2003 until 2012. |
Kurt Wheeler |
Mr. Kurt C. Wheeler is Independent Director of Globus Medical, Inc. He has been a co-founder and Managing Director of Clarus Ventures, LLC, a life sciences venture capital firm, since its inception in 2005. He has served as one of directors since July 2007 and is a member of Compensation Committee. He has over 25 years of direct investment and industry experience within the healthcare sector, including being a General Partner at MPM Capital, L.P., a healthcare venture capital firm, since 2000. Mr. Wheeler co-founded and served as CEO of InControl (NASDAQ: INCL), a publicly-traded medical device company that was acquired by Guidant Corporation in 1998. Prior to founding InControl, he was a Principal with the Mayfield Fund, a private equity firm, where he focused on healthcare investing. Mr. Wheeler began his career with Eli Lilly & Co., a pharmaceutical company. Mr. Wheeler also sits on the boards of directors of SFJ Pharmaceuticals, Inc., Zogenix, Inc. (NASDAQ: ZGNX), Flowonix, and Cardiac Dimensions, Inc. Previously, he was responsible for investments in the following medical device companies: Hemosense (AMEX: HEM); Intratherapeutics, Inc. and SenoRx, Inc. (NASDAQ: SENO), and the following biopharmaceutical companies: Eyetech Pharmaceuticals, Inc. (NASDAQ: EYET); Neuromed Pharmaceuticals, Ltd. (NASDAQ: CRXX) and Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX). Mr. Wheeler holds a B.A. from Brigham Young University and an M.B.A. from Northwestern University. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
David Paul |
1,133,100 |
David Demski |
897,375 |
Richard Baron |
1,176,020 |
A. Brett Murphy |
695,770 |
David Davidar |
-- |
Daniel Lemaitre |
-- |
Robert Liptak |
-- |
Ann Rhoads |
-- |
Kurt Wheeler |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
David Paul |
0 | 0 |
David Demski |
0 | 0 |
Richard Baron |
0 | 0 |
A. Brett Murphy |
0 | 0 |
David Davidar |
0 | 0 |
Daniel Lemaitre |
0 | 0 |
Robert Liptak |
0 | 0 |
Ann Rhoads |
0 | 0 |
Kurt Wheeler |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
DAVIDAR DAVID D |
10,000 | $17.15 |
DAVIDAR DAVID D |
20,000 | $16.56 |
DAVIDAR DAVID D |
22,500 | $17.17 |
DAVIDAR DAVID D |
52,500 | $17.17 |
DAVIDAR DAVID D |
52,500 | $16.25 |
DAVIDAR DAVID D |
22,500 | $16.25 |
DAVIDAR DAVID D |
35,000 | $0.00 |
DAVIDAR DAVID D |
35,000 | $0.00 |
DEMSKI DAVID M |
40,000 | $16.25 |
DAVIDAR DAVID D |
465,894 | $0.00 |
DAVIDAR DAVID D |
104,927 | $0.00 |
DAVIDAR DAVID D |
360,967 | $0.00 |
DEMSKI DAVID M |
14,225 | $15.00 |
DEMSKI DAVID M |
25,775 | $15.00 |
MURPHY ANDREW BRETT |
31,103 | $12.87 |
DEMSKI DAVID M |
50,000 | $0.00 |
WHEELER KURT C |
804,232 | $11.16 |
DEMSKI DAVID M |
98,957 | $11.16 |
PAYNE STEVEN |
2,305 | $11.16 |
LIPTAK ROBERT |
804,232 | $11.16 |
DAVIDAR DAVID D |
1,141,157 | $0.00 |
GOLDMAN SACHS PRIVATE EQUITY PARTNERS OFFSHORE HOLDINGS L P |
7,089,681 | $0.00 |
MURPHY ANDREW BRETT |
92,307 | $0.00 |
MURPHY ANDREW BRETT |
16,910 | $11.16 |
LIPTAK ROBERT |
7,444,168 | $0.00 |

